Does the media favor PCVX or GLUE?

In the previous week, Vaxcyte had 2 more articles in the media than Monte Rosa Therapeutics. MarketBeat recorded 5 mentions for Vaxcyte and 3 mentions for Monte Rosa Therapeutics. Vaxcyte's average media sentiment score of 1.45 beat Monte Rosa Therapeutics' score of 1.21 indicating that Vaxcyte is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vaxcyte 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Monte Rosa Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to GLUE or IBRX?

In the previous week, ImmunityBio had 2 more articles in the media than Monte Rosa Therapeutics. MarketBeat recorded 5 mentions for ImmunityBio and 3 mentions for Monte Rosa Therapeutics. ImmunityBio's average media sentiment score of 1.82 beat Monte Rosa Therapeutics' score of 1.21 indicating that ImmunityBio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Monte Rosa Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ImmunityBio 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media refer more to GLUE or MIRM?

In the previous week, Mirum Pharmaceuticals had 1 more articles in the media than Monte Rosa Therapeutics. MarketBeat recorded 4 mentions for Mirum Pharmaceuticals and 3 mentions for Monte Rosa Therapeutics. Monte Rosa Therapeutics' average media sentiment score of 1.21 beat Mirum Pharmaceuticals' score of 0.88 indicating that Monte Rosa Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Monte Rosa Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mirum Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer RYTM or GLUE?

In the previous week, Rhythm Pharmaceuticals had 5 more articles in the media than Monte Rosa Therapeutics. MarketBeat recorded 8 mentions for Rhythm Pharmaceuticals and 3 mentions for Monte Rosa Therapeutics. Monte Rosa Therapeutics' average media sentiment score of 1.21 beat Rhythm Pharmaceuticals' score of 0.79 indicating that Monte Rosa Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rhythm Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Monte Rosa Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer LNTH or GLUE?

In the previous week, Lantheus had 1 more articles in the media than Monte Rosa Therapeutics. MarketBeat recorded 4 mentions for Lantheus and 3 mentions for Monte Rosa Therapeutics. Lantheus' average media sentiment score of 1.35 beat Monte Rosa Therapeutics' score of 1.21 indicating that Lantheus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lantheus 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Monte Rosa Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Monte Rosa Therapeutics (GLUE) Competitors

$22.78 -0.25 (-1.09%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$22.99 +0.21 (+0.92%)

As of 07/24/2026 07:34 PM Eastern

Compare

GLUE vs. PCVX, IBRX, MIRM, RYTM, and LNTH

Should you buy Monte Rosa Therapeutics stock or one of its competitors? MarketBeat compares Monte Rosa Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Monte Rosa Therapeutics include Vaxcyte (PCVX), ImmunityBio (IBRX), Mirum Pharmaceuticals (MIRM), Rhythm Pharmaceuticals (RYTM), and Lantheus (LNTH). These companies are all part of the "pharmaceutical products" industry.

How does Monte Rosa Therapeutics compare to Vaxcyte?

Vaxcyte (NASDAQ:PCVX) and Monte Rosa Therapeutics (NASDAQ:GLUE) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, risk, earnings, dividends, valuation, profitability and analyst recommendations.

Vaxcyte has a beta of 1.22, meaning that its stock price is 22% more volatile than the broader market. Comparatively, Monte Rosa Therapeutics has a beta of 1.56, meaning that its stock price is 56% more volatile than the broader market.

In the previous week, Vaxcyte had 2 more articles in the media than Monte Rosa Therapeutics. MarketBeat recorded 5 mentions for Vaxcyte and 3 mentions for Monte Rosa Therapeutics. Vaxcyte's average media sentiment score of 1.45 beat Monte Rosa Therapeutics' score of 1.21 indicating that Vaxcyte is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vaxcyte	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Monte Rosa Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Vaxcyte has a net margin of 0.00% compared to Monte Rosa Therapeutics' net margin of -302.69%. Vaxcyte's return on equity of -32.51% beat Monte Rosa Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vaxcyte	N/A	-32.51%	-29.51%
Monte Rosa Therapeutics	-302.69%	-40.99%	-25.94%

96.8% of Vaxcyte shares are held by institutional investors. Comparatively, 80.0% of Monte Rosa Therapeutics shares are held by institutional investors. 3.3% of Vaxcyte shares are held by company insiders. Comparatively, 6.4% of Monte Rosa Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Vaxcyte presently has a consensus target price of $86.00, indicating a potential upside of 57.34%. Monte Rosa Therapeutics has a consensus target price of $33.33, indicating a potential upside of 46.33%. Given Vaxcyte's higher possible upside, research analysts clearly believe Vaxcyte is more favorable than Monte Rosa Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vaxcyte	2 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.44
Monte Rosa Therapeutics	2 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.56

Monte Rosa Therapeutics has higher revenue and earnings than Vaxcyte. Monte Rosa Therapeutics is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaxcyte	N/A	N/A	-$766.63M	-$6.88	N/A
Monte Rosa Therapeutics	$123.67M	15.56	-$38.63M	-$1.48	N/A

Summary

Monte Rosa Therapeutics beats Vaxcyte on 8 of the 15 factors compared between the two stocks.

How does Monte Rosa Therapeutics compare to ImmunityBio?

Monte Rosa Therapeutics (NASDAQ:GLUE) and ImmunityBio (NASDAQ:IBRX) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, analyst recommendations, profitability, dividends and earnings.

Monte Rosa Therapeutics has a beta of 1.56, suggesting that its share price is 56% more volatile than the broader market. Comparatively, ImmunityBio has a beta of 0.01, suggesting that its share price is 99% less volatile than the broader market.

80.0% of Monte Rosa Therapeutics shares are held by institutional investors. Comparatively, 8.6% of ImmunityBio shares are held by institutional investors. 6.4% of Monte Rosa Therapeutics shares are held by company insiders. Comparatively, 66.1% of ImmunityBio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Monte Rosa Therapeutics has higher earnings, but lower revenue than ImmunityBio. Monte Rosa Therapeutics is trading at a lower price-to-earnings ratio than ImmunityBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Monte Rosa Therapeutics	$123.67M	15.56	-$38.63M	-$1.48	N/A
ImmunityBio	$140.98M	52.75	-$351.40M	-$0.85	N/A

In the previous week, ImmunityBio had 2 more articles in the media than Monte Rosa Therapeutics. MarketBeat recorded 5 mentions for ImmunityBio and 3 mentions for Monte Rosa Therapeutics. ImmunityBio's average media sentiment score of 1.82 beat Monte Rosa Therapeutics' score of 1.21 indicating that ImmunityBio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Monte Rosa Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ImmunityBio	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Monte Rosa Therapeutics presently has a consensus target price of $33.33, suggesting a potential upside of 46.33%. ImmunityBio has a consensus target price of $14.20, suggesting a potential upside of 100.00%. Given ImmunityBio's stronger consensus rating and higher probable upside, analysts clearly believe ImmunityBio is more favorable than Monte Rosa Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Monte Rosa Therapeutics	2 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.56
ImmunityBio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Monte Rosa Therapeutics has a net margin of -302.69% compared to ImmunityBio's net margin of -606.15%. ImmunityBio's return on equity of 0.00% beat Monte Rosa Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Monte Rosa Therapeutics	-302.69%	-40.99%	-25.94%
ImmunityBio	-606.15%	N/A	-59.53%

Summary

ImmunityBio beats Monte Rosa Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Monte Rosa Therapeutics compare to Mirum Pharmaceuticals?

Monte Rosa Therapeutics (NASDAQ:GLUE) and Mirum Pharmaceuticals (NASDAQ:MIRM) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, earnings, profitability, media sentiment, analyst recommendations, risk and institutional ownership.

Mirum Pharmaceuticals has a net margin of -140.24% compared to Monte Rosa Therapeutics' net margin of -302.69%. Mirum Pharmaceuticals' return on equity of -11.28% beat Monte Rosa Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Monte Rosa Therapeutics	-302.69%	-40.99%	-25.94%
Mirum Pharmaceuticals	-140.24%	-11.28%	-3.84%

Monte Rosa Therapeutics has a beta of 1.56, meaning that its stock price is 56% more volatile than the broader market. Comparatively, Mirum Pharmaceuticals has a beta of 0.48, meaning that its stock price is 52% less volatile than the broader market.

Mirum Pharmaceuticals has higher revenue and earnings than Monte Rosa Therapeutics. Monte Rosa Therapeutics is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Monte Rosa Therapeutics	$123.67M	15.56	-$38.63M	-$1.48	N/A
Mirum Pharmaceuticals	$569.61M	12.10	-$23.36M	-$13.61	N/A

Monte Rosa Therapeutics currently has a consensus price target of $33.33, indicating a potential upside of 46.33%. Mirum Pharmaceuticals has a consensus price target of $143.40, indicating a potential upside of 26.87%. Given Monte Rosa Therapeutics' higher possible upside, equities analysts plainly believe Monte Rosa Therapeutics is more favorable than Mirum Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Monte Rosa Therapeutics	2 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.56
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93

80.0% of Monte Rosa Therapeutics shares are held by institutional investors. 6.4% of Monte Rosa Therapeutics shares are held by company insiders. Comparatively, 8.3% of Mirum Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Mirum Pharmaceuticals had 1 more articles in the media than Monte Rosa Therapeutics. MarketBeat recorded 4 mentions for Mirum Pharmaceuticals and 3 mentions for Monte Rosa Therapeutics. Monte Rosa Therapeutics' average media sentiment score of 1.21 beat Mirum Pharmaceuticals' score of 0.88 indicating that Monte Rosa Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Monte Rosa Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Mirum Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Mirum Pharmaceuticals beats Monte Rosa Therapeutics on 11 of the 17 factors compared between the two stocks.

How does Monte Rosa Therapeutics compare to Rhythm Pharmaceuticals?

Rhythm Pharmaceuticals (NASDAQ:RYTM) and Monte Rosa Therapeutics (NASDAQ:GLUE) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, media sentiment, valuation, institutional ownership, earnings and analyst recommendations.

80.0% of Monte Rosa Therapeutics shares are owned by institutional investors. 5.9% of Rhythm Pharmaceuticals shares are owned by insiders. Comparatively, 6.4% of Monte Rosa Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Monte Rosa Therapeutics has lower revenue, but higher earnings than Rhythm Pharmaceuticals. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Monte Rosa Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rhythm Pharmaceuticals	$189.76M	36.87	-$196.54M	-$3.13	N/A
Monte Rosa Therapeutics	$123.67M	15.56	-$38.63M	-$1.48	N/A

Rhythm Pharmaceuticals currently has a consensus target price of $138.29, indicating a potential upside of 35.44%. Monte Rosa Therapeutics has a consensus target price of $33.33, indicating a potential upside of 46.33%. Given Monte Rosa Therapeutics' higher probable upside, analysts clearly believe Monte Rosa Therapeutics is more favorable than Rhythm Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rhythm Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.76
Monte Rosa Therapeutics	2 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.56

Rhythm Pharmaceuticals has a net margin of -93.33% compared to Monte Rosa Therapeutics' net margin of -302.69%. Monte Rosa Therapeutics' return on equity of -40.99% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rhythm Pharmaceuticals	-93.33%	-203.25%	-44.99%
Monte Rosa Therapeutics	-302.69%	-40.99%	-25.94%

Rhythm Pharmaceuticals has a beta of 1.88, suggesting that its stock price is 88% more volatile than the broader market. Comparatively, Monte Rosa Therapeutics has a beta of 1.56, suggesting that its stock price is 56% more volatile than the broader market.

In the previous week, Rhythm Pharmaceuticals had 5 more articles in the media than Monte Rosa Therapeutics. MarketBeat recorded 8 mentions for Rhythm Pharmaceuticals and 3 mentions for Monte Rosa Therapeutics. Monte Rosa Therapeutics' average media sentiment score of 1.21 beat Rhythm Pharmaceuticals' score of 0.79 indicating that Monte Rosa Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rhythm Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Monte Rosa Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Monte Rosa Therapeutics beats Rhythm Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Monte Rosa Therapeutics compare to Lantheus?

Lantheus (NASDAQ:LNTH) and Monte Rosa Therapeutics (NASDAQ:GLUE) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, risk, analyst recommendations and media sentiment.

In the previous week, Lantheus had 1 more articles in the media than Monte Rosa Therapeutics. MarketBeat recorded 4 mentions for Lantheus and 3 mentions for Monte Rosa Therapeutics. Lantheus' average media sentiment score of 1.35 beat Monte Rosa Therapeutics' score of 1.21 indicating that Lantheus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lantheus	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Monte Rosa Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Lantheus has a beta of -0.06, meaning that its stock price is 106% less volatile than the broader market. Comparatively, Monte Rosa Therapeutics has a beta of 1.56, meaning that its stock price is 56% more volatile than the broader market.

Lantheus has a net margin of 18.05% compared to Monte Rosa Therapeutics' net margin of -302.69%. Lantheus' return on equity of 29.32% beat Monte Rosa Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantheus	18.05%	29.32%	15.00%
Monte Rosa Therapeutics	-302.69%	-40.99%	-25.94%

99.1% of Lantheus shares are owned by institutional investors. Comparatively, 80.0% of Monte Rosa Therapeutics shares are owned by institutional investors. 1.7% of Lantheus shares are owned by insiders. Comparatively, 6.4% of Monte Rosa Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Lantheus presently has a consensus price target of $110.43, suggesting a potential upside of 5.35%. Monte Rosa Therapeutics has a consensus price target of $33.33, suggesting a potential upside of 46.33%. Given Monte Rosa Therapeutics' higher probable upside, analysts plainly believe Monte Rosa Therapeutics is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantheus	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73
Monte Rosa Therapeutics	2 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.56

Lantheus has higher revenue and earnings than Monte Rosa Therapeutics. Monte Rosa Therapeutics is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantheus	$1.54B	4.43	$233.56M	$4.15	25.26
Monte Rosa Therapeutics	$123.67M	15.56	-$38.63M	-$1.48	N/A

Summary

Lantheus beats Monte Rosa Therapeutics on 12 of the 16 factors compared between the two stocks.

Get Monte Rosa Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GLUE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GLUE vs. The Competition

Export

Metric	Monte Rosa Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.95B	$3.67B	$6.87B	$12.28B
Dividend Yield	N/A	2.19%	2.67%	9.79%
P/E Ratio	-15.39	21.29	27.11	23.71
Price / Sales	15.56	161.49	496.35	75.28
Price / Cash	N/A	157.90	50.54	59.64
Price / Book	6.36	7.88	10.28	6.07
Net Income	-$38.63M	$23.86M	$3.60B	$331.99M
7 Day Performance	-7.25%	-3.82%	-1.27%	-0.63%
1 Month Performance	5.17%	-2.61%	-0.37%	-2.00%
1 Year Performance	301.76%	32.79%	18.30%	13.62%

Monte Rosa Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GLUE Monte Rosa Therapeutics	2.9179 of 5 stars	$22.78 -1.1%	$33.33 +46.3%	+298.9%	$1.95B	$123.67M	N/A	90	Positive News
PCVX Vaxcyte	2.8886 of 5 stars	$56.29 +0.4%	$86.00 +52.8%	+50.8%	$8.13B	N/A	N/A	160	Positive News
IBRX ImmunityBio	2.8234 of 5 stars	$7.73 +3.8%	$14.20 +83.6%	+135.9%	$8.08B	$113.29M	N/A	590	Positive News
MIRM Mirum Pharmaceuticals	2.8946 of 5 stars	$118.61 +1.1%	$143.40 +20.9%	+116.7%	$7.23B	$521.31M	N/A	140	Upcoming Earnings
RYTM Rhythm Pharmaceuticals	2.9798 of 5 stars	$105.34 -0.7%	$138.29 +31.3%	+17.0%	$7.21B	$189.76M	N/A	140	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GLUE) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Monte Rosa Therapeutics (GLUE) Competitors

GLUE vs. PCVX, IBRX, MIRM, RYTM, and LNTH

How does Monte Rosa Therapeutics compare to Vaxcyte?

Summary

How does Monte Rosa Therapeutics compare to ImmunityBio?

Summary

How does Monte Rosa Therapeutics compare to Mirum Pharmaceuticals?

Summary

How does Monte Rosa Therapeutics compare to Rhythm Pharmaceuticals?

Summary

How does Monte Rosa Therapeutics compare to Lantheus?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GLUE vs. The Competition

Monte Rosa Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Monte Rosa Therapeutics (GLUE) Competitors

GLUE vs. PCVX, IBRX, MIRM, RYTM, and LNTH

How does Monte Rosa Therapeutics compare to Vaxcyte?

Which has more volatility and risk, PCVX or GLUE?

Does the media favor PCVX or GLUE?

Is PCVX or GLUE more profitable?

Do insiders & institutionals have more ownership in PCVX or GLUE?

Do analysts recommend PCVX or GLUE?

Which has higher earnings & valuation, PCVX or GLUE?

Summary

How does Monte Rosa Therapeutics compare to ImmunityBio?

Which has more risk & volatility, GLUE or IBRX?

Do insiders & institutionals believe in GLUE or IBRX?

Which has better earnings & valuation, GLUE or IBRX?

Does the media refer more to GLUE or IBRX?

Do analysts prefer GLUE or IBRX?

Is GLUE or IBRX more profitable?

Summary

How does Monte Rosa Therapeutics compare to Mirum Pharmaceuticals?

Is GLUE or MIRM more profitable?

Which has more volatility and risk, GLUE or MIRM?

Which has better earnings & valuation, GLUE or MIRM?

Do analysts recommend GLUE or MIRM?

Do institutionals and insiders have more ownership in GLUE or MIRM?

Does the media refer more to GLUE or MIRM?

Summary

How does Monte Rosa Therapeutics compare to Rhythm Pharmaceuticals?

Do insiders and institutionals have more ownership in RYTM or GLUE?

Which has preferable valuation and earnings, RYTM or GLUE?

Do analysts rate RYTM or GLUE?

Is RYTM or GLUE more profitable?

Which has more risk and volatility, RYTM or GLUE?

Does the media prefer RYTM or GLUE?

Summary

How does Monte Rosa Therapeutics compare to Lantheus?

Does the media prefer LNTH or GLUE?

Which has more risk & volatility, LNTH or GLUE?

Is LNTH or GLUE more profitable?

Do insiders & institutionals have more ownership in LNTH or GLUE?

Do analysts rate LNTH or GLUE?

Which has stronger valuation & earnings, LNTH or GLUE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GLUE vs. The Competition

Monte Rosa Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools